Joseph Schwartz analyst

Currently out of the existing stock ratings of Joseph Schwartz, 270 are a BUY (82.07%), 55 are a HOLD (16.72%), 4 are a SELL (1.22%).

Joseph Schwartz

Work Performance Price Targets & Ratings Chart

Analyst Joseph Schwartz, carries an average stock price target met ratio of 61.79% that have a potential upside of 44.57% achieved within 390 days. Previously, Joseph Schwartz worked at LEERINK.

Joseph Schwartz’s has documented 650 price targets and ratings displayed on 58 stocks. The coverage was on Healthcare, Energy, Financial Services sectors.

Most recent stock forecast was given on QURE, Uniqure NV at 18-Jun-2026.

Wall Street Analyst Joseph Schwartz

Analyst best performing recommendations are on LRMR (LARIMAR THERAPEUTICS).
The best stock recommendation documented was for LRMR (LARIMAR THERAPEUTICS) at 12/1/2015. The price target of $132 was fulfilled within 1 day with a profit of $59.16 (30.95%) receiving and performance score of 309.48.

Average potential price target upside

AMAG AMAG Pharmaceuticals ARNA Arena Pharmaceuticals ASND Ascendis Pharma AS AUPH Aurinia Pharmaceuticals BMRN Biomarin Pharmaceutical CCXI ChemoCentryx FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals MDCO The Medicines Company PTGX Protagonist Therapeutics QURE Uniqure NV RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences  SRPT Sarepta Therapeutics AMTI Applied Molecular Transport  BIIB Biogen CBAY Cymabay Therapeu ACHN Achillion Pharmaceuticals EWTX Edgewise Therapeutics GOSS Gossamer Bio IFRX InflaRx N.V. IMRA Imara INSM Insmed ONCE Spark Therapeutics RETA Reata Pharmaceuticals RPHM Reneo Pharmaceuticals BOLD Audentes Therapeutics DSGN Design Therapeutics PHVS Pharvaris BV RNA Avidity Biosciences  TVTX Travere Therapeutics UTHR United Therapeutics ZFGN Zafgen KALV Kalvista Pharmaceuticals REGN Regeneron Pharmaceuticals SYBX Synlogic ALDR Alder BioPharmaceuticals CRNX Crinetics Pharmaceuticals KDNY Chinook Therapeutics PTI Proteostasis Therapeutics RTRX Travere Therapeutics ANTX AN2 Therapeutics LRMR Larimar Therapeutics FULC Fulcrum Therapeutics MREO Mereo BioPharma Group PLC ADR RGLS Regulus Therapeutics APLT Applied Therapeutics ISEE IVERIC bio ACH Aluminum Corp of China Ltd ADR AMT American Tower Corp AR Antero Resources Corp CB Chubb Ltd DBVT DBV Technologies KD Kyndryl Holdings MD Mednax SELB Selecta Biosciences PDSB PDS Biotechnology Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Oct-2020

$13.75

$14

5 years 9 months 24 days ago
(05-Oct-2020)

10/15 (66.67%)

$0.67 (5.12%)

51

Hold Since 02-Oct-2020

$13.75

$14

5 years 9 months 27 days ago
(02-Oct-2020)

4/7 (57.14%)

$0.01 (0.07%)

109

Hold Since 12-Jun-2015

$10

5 years 11 months 10 days ago
(19-Aug-2020)

7/10 (70%)

$-0.63 (-5.93%)

139

Hold Since 18-Aug-2020

$10

$-3.75 (-27.27%)

$20

5 years 11 months 11 days ago
(18-Aug-2020)

1/4 (25%)

$-0.63 (-5.93%)

6

Hold Since 21-May-2018

$10

$-3.75 (-27.27%)

5 years 11 months 22 days ago
(07-Aug-2020)

1/3 (33.33%)

$-0.55 (-5.21%)

17

Show more analysts

Please expand the browser size to see the chart

Which stock is Joseph Schwartz is most bullish on?

Potential upside of $108.08 has been obtained for INSM (INSMED)

Which stock is Joseph Schwartz is most reserved on?

Potential downside of $0.28 has been obtained for FULC (FULCRUM THERAPEUTICS)

What Year was the first public recommendation made by Joseph Schwartz?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?